arrow
N

Nicolaus Kröger

University Medical Center Hamburg-Eppendorf
H指数:101
被引数:4.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

GvHD prophylaxis in elderly patients: post-transplant cyclophosphamide or ATG? A study by the EBMT transplant complications working party

老年患者移植排斥反应预防:移植后环磷酰胺还是抗胸腺细胞球蛋白?EBMT移植并发症工作组研究

2026-10-060
PRE
Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome in young adults: A retrospective study on behalf of the EBMT Chronic Malignancies Working Party

异基因造血细胞移植治疗年轻成人骨髓增生异常综合征:代表EBMT慢性恶性疾病工作组进行的回顾性研究

2026-09-300
OA
HHV-6B encephalitis after allogeneic stem cell transplantation: a single center cohort study

人巨细胞病毒6B型脑炎在异基因干细胞移植后的发生:一项单中心队列研究

2026-09-240
PRE
A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia

异基因移植后急性白血病患者无白血病生存的综合性预后模型

2026-07-020
OA
The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL)

IPI风险因素对复发或难治性大B细胞淋巴瘤(LBCL)治疗中CAR T细胞疗法或同种异体干细胞移植的影响

2026-06-190
PRE
Allogeneic hematopoietic cell transplantation for T-cell/histiocyte-rich large B-cell lymphoma: An EBMT lymphoma working party study

异基因造血细胞移植治疗T细胞/组织细胞富集型大B细胞淋巴瘤:一项EBMT淋巴瘤工作组研究

Leukemia
IF13.4
2026-06-150
OAAI
Brentuximab Vedotin after AlloSCT for Relapsed/Refractory Hodgkin Lymphoma: GHSG BV-ALLO Phase II Trial

异基因造血干细胞移植后复发/难治性霍奇金淋巴瘤使用 Brentuximab Vedotin 的治疗:GHSG BV-ALLO II 期临床试验

2026-06-120
OAAI
Survival trends in young adults with acute leukaemia after AHSCT in Germany: comparisons with younger and older patients

德国年轻成人急性白血病自体造血干细胞移植后的生存趋势:与更年轻和更年长患者的比较

2026-04-120
PREAI
Outcomes of allogeneic transplantation in blast-phase myeloproliferative neoplasms: one-third achieve long-term survival

异基因移植在 blasts 期骨髓增殖性肿瘤中的疗效:约三分之一患者实现长期生存

2026-04-010
OAAI
PTCy or ATG for Matched Transplantation in Myelofibrosis

为骨髓纤维化患者进行匹配移植的PTCy或ATG治疗方案

2026-02-230
OAAI
Impact of anti-T-lymphocyte globulin dosing on graft versus host disease in matched sibling peripheral blood stem cell transplantation
2026-01-210
OAAI
Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report

造血干细胞移植对于实现再生障碍性贫血后髓系肿瘤的长期生存有效:欧洲血液和骨髓移植学会严重再生障碍性贫血报告

2026-01-010
OA
Pretransplant HMA and Venetoclax in AML patients – a Real-World Analysis from the Cooperative Transplant Study Group

移植前HMA和Venetoclax在AML患者中的应用——来自合作移植研究组的真实世界分析

2025-12-150
OAAI
Posttransplant cyclophosphamide versus antithymocyte globulin in patients with cardiovascular comorbidity undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukaemia in first complete remission from unrelated donors: a retrospective matched-pair analysis from the ALWP of the EBMT

移植后环磷酰胺与抗胸腺细胞球蛋白在合并心血管并发症、接受无关供者异基因造血细胞移植治疗首次完全缓解期急性髓系白血病患者中的比较:一项来自EBMT ALWP的回顾性配对分析

2025-12-030
OAAI
TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in amulti-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

TET2突变不影响接受造血干细胞移植且处于首次缓解期的成人急性髓系白血病患者的预后:欧洲血液与骨髓移植学会全球委员会和急性白血病工作组的多中心回顾性分析显示,配型相合的同胞或无关供者移植与单倍型相合供者移植后的结果相似。

2025-12-010
OAAI
Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary AML in First Complete Remission: A Study From the ALWP/EBMT

与来自相合同胞或无关供者的异基因移植相比,非T细胞耗竭的半相合移植在二次急性髓系白血病首次完全缓解期患者中的应用:一项来自ALWP/EBMT的研究

2025-12-010
OAAI
Comparison of anti-human T cell globulins on immune reconstitution and early infections after autologous transplant in patients with multiple sclerosis

抗人T细胞球蛋白在多发性硬化患者自体移植后的免疫重建和早期感染中的比较

2025-11-270
OAAI
Donor selection in PTCy haploidentical transplant for acute lymphoblastic leukemia: a study from the ALWP of the EBMT

供者选择在PTCy半相合移植治疗急性淋巴细胞白血病中的应用:一项来自EBMT ALWP的研究

2025-11-250
PRE